In August 2019, the FDA approved entrectinib for treatment of adult patients with metastatic non-small cell lung cancer that is ROS1-positive.
Mallory Norman, BS, PharmD Candidate and Lisa M. Holle, PharmD, BCOP, FHOPA
Advertisement
Articles by Mallory Norman, BS, PharmD Candidate and Lisa M. Holle, PharmD, BCOP, FHOPA
Advertisement
Latest Updated Articles
Entrectinib for ROS1-Positive NSCLC and NTRK-Positive Solid TumorsPublished: May 8th 2020 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Most Favored Nation, Direct-to-Consumer Strategies Reshape US Pharma Landscape, Challenging Traditional Care
2
FDA Approves Lumateperone as Adjunct Therapy for Major Depressive Disorder
3
A1c Monitoring Could Be Delayed Up to 2 Years for Patients With Type 2 Diabetes
4
Wicked Good Cardiometabolic Chat: SGLT2is Offer Cardiorenal Benefits Beyond Diabetes
5
